PARK2在癌症中的新作用。
An emerging role of PARK2 in cancer.
作者信息
Xu Liang, Lin De-chen, Yin Dong, Koeffler H Phillip
机构信息
Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
出版信息
J Mol Med (Berl). 2014 Jan;92(1):31-42. doi: 10.1007/s00109-013-1107-0. Epub 2013 Dec 3.
PARK2 (PARKIN) is an E3 ubiquitin ligase involved in multiple signaling pathways and cellular processes. Activity of PARK2 is tightly regulated through inter- and intra-molecular interactions. Dysfunction of PARK2 is associated with the progression of parkinsonism. Notably, frequent PARK2 inactivation has been identified in various human cancers. Park2-deficient mice are more susceptible to tumorigenesis, indicating its crucial role as a tumor suppressor. However, biological studies also show that PARK2 possesses both pro-survival and growth suppressive functions. Here, we summarize the genetic lesions of PARK2 in human cancers and discuss the current knowledge of PARK2 in cancer progression. We further highlight future efforts for the study of PARK2 in cancer.
PARK2（帕金蛋白）是一种参与多种信号通路和细胞过程的E3泛素连接酶。PARK2的活性通过分子间和分子内相互作用受到严格调控。PARK2功能障碍与帕金森病的进展相关。值得注意的是，在各种人类癌症中已发现PARK2频繁失活。Park2基因缺陷的小鼠更易发生肿瘤，表明其作为肿瘤抑制因子的关键作用。然而，生物学研究也表明PARK2具有促生存和生长抑制功能。在此，我们总结了人类癌症中PARK2的基因损伤情况，并讨论了目前关于PARK2在癌症进展方面的认识。我们还进一步强调了未来对癌症中PARK2进行研究的工作重点。
Zotero 插件